trabectedin

Trabectedin (Ecteinascidin 743) has potent antitumor activity and the potential for soft tissue sarcoma and ovarian cancer research. Trabectedin inhibits cell growth of MX-1, MCF7 and MCF7/DXR cells with IC50 values of 0.1 nM, 1.5 nM and 3.7 nM, respectively.

Trabectedin derivative 1 TFA is a selective DNA minor groove binder that inhibits DNA transcription and repair processes, leading to the induction of apoptosis in tumor cells. It shows potential for research in solid tumors such as soft tissue sarcoma and ovarian cancer.

Trabectedin derivative 2 TFA (compound PL-12) is a Trabectedin derivative suitable for cancer research.

Anticanceragent 179 (Compound 3) is an analog of trabectedin. It has the ability to inhibit the migration of MDA-MB-231 breast cancer cells.